The company’s core competency is developing next generation sequencing assays that characterize the adaptive immune system, serving as a platform technology to the research community and the biopharmaceutical industry. Its flagship commercial product, immunoSEQ, uses a proprietary immune profiling assay to analyze T cells and B cells – critical components of the adaptive immune system’s defense against disease – with unprecedented depth and specificity. Sequencing the variable region of these immune cells allows researchers to characterize the complete immune repertoire of a patient or group of patients in search of immunologic biomarkers. Fueled by discoveries from immunoSEQ, the company is currently developing a pipeline of clinical assays that are specific to cancer diagnosis and prognosis. All of Adaptive Biotechnologies’ assays are coupled with a cloud-computing infrastructure that simplifies the interpretation of massive quantities of data in a user-friendly interface. immunoSEQ was launched in September 2010 and has a worldwide customer base.

Show more
Seattle, US
Size (employees)
239 (est)+2%
Adaptive Biotechnologies was founded in 2009 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Adaptive Biotechnologies

Chad Robins

Chad Robins

President, Chief Executive Officer and Co-founder
Chad Cohen

Chad Cohen

Chief Financial Officer
Sean Nolan

Sean Nolan

Chief Technology Officer
Harlan Robins

Harlan Robins

Chief Scientific Officer, Co-founder
Nancy Hill

Nancy Hill

Senior Vice President of Commercial Operations

Adaptive Biotechnologies Office Locations

Adaptive Biotechnologies has offices in Seattle and South San Francisco
Seattle, US (HQ)
200 1551 Eastlake Ave E
South San Francisco, US
100 329 Oyster Point Blvd
Show all (2)
Report incorrect company information

Adaptive Biotechnologies Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$539 m

Latest funding size

$206.20 m

Time since last funding

3 years ago


Adaptive Biotechnologies's latest funding round in May 2015 was reported to be $206.2 m. In total, Adaptive Biotechnologies has raised $539 m. Adaptive Biotechnologies's latest valuation is reported to be $1.1 b.
Show all funding rounds

Adaptive Biotechnologies Financials

Market valuation

1.1 b
Show all financial metrics
Report incorrect company information